GlassScriptPhysician profile
Mathew G Mathai
NPI 1104854363
$28,337.72
in general payments reported to CMS, 2019-2025
17 companies · $64.29 in 2025
The $64.29 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $2,085 · 2021: $3,650 · 2022: $512 · 2023: $105 · 2024: $4,793 · 2025: $64.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,204 · Travel and Lodging: $949 · Food and Beverage: $771 · Education: $38.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,204.00 |
| Travel and Lodging | $948.75 |
| Food and Beverage | $771.45 |
| Education | $38.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $22,162.90 | 2019-2025 | Jascayd, Ofev |
| Mylan Specialty L.P. | $4,605.40 | 2019-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $356.87 | 2019-2024 | Fasenra |
| Genentech USA, INC. | $239.10 | 2019-2023 | Xolair |
| Baxter Healthcare | $189.10 | 2022-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Glaxosmithkline, LLC. | $164.57 | 2022-2023 | Trelegy Ellipta |
| Philips North America LLC | $136.54 | 2021 | |
| Insmed, INC. | $123.77 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $111.29 | 2019 | |
| Jazz Pharmaceuticals INC. | $85.47 | 2023-2024 | |
| Csl Behring | $48.52 | 2020 | |
| Genzyme Corporation | $33.62 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $23.26 | 2021 | |
| Astellas Pharma US INC | $15.97 | 2019 | |
| Advanced Respiratory, INC | $14.97 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $13.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Mathai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.